Phio Pharmaceuticals Yönetim

Yönetim kriter kontrolleri 2/4

Phio Pharmaceuticals CEO'su Bob Bitterman, Feb2023 tarihinde atandı, in görev süresi 1.75 yıldır. in toplam yıllık tazminatı $ 437.89K olup, şirket hissesi ve opsiyonları dahil olmak üzere 86.8% maaş ve 13.2% ikramiyelerden oluşmaktadır. şirketin hisselerinin 0.2% ine doğrudan sahiptir ve bu hisseler $ 5.37K değerindedir. Yönetim ekibinin ve yönetim kurulunun ortalama görev süresi sırasıyla 1.5 yıl ve 7.4 yıldır.

Anahtar bilgiler

Bob Bitterman

İcra Kurulu Başkanı

US$437.9k

Toplam tazminat

CEO maaş yüzdesi	86.8%
CEO görev süresi	1.8yrs
CEO sahipliği	0.2%
Yönetim ortalama görev süresi	1.5yrs
Yönetim Kurulu ortalama görev süresi	7.4yrs

Son yönetim güncellemeleri

Recent updates

Phio Pharmaceuticals appoints interim executive chairman

Sep 29

Phio Pharmaceuticals GAAP EPS of -$0.19 beats by $0.12

Aug 11

Is Phio Pharmaceuticals (NASDAQ:PHIO) In A Good Position To Deliver On Growth Plans?

Apr 11

Phio soars 22% on positive in vivo data on combination PD-1 and TIGIT therapy in cancer

Nov 09

CEO Tazminat Analizi

Bob Bitterman'un ücretlendirmesi Phio Pharmaceuticals'un kazancına kıyasla nasıl değişti?
Tarih	Toplam Tazminat	Maaş	Şirket Kazançları
Jun 30 2024	n/a	n/a	-US$9m
Mar 31 2024	n/a	n/a	-US$9m
Dec 31 2023	US$438k	US$380k	-US$11m
Sep 30 2023	n/a	n/a	-US$12m
Jun 30 2023	n/a	n/a	-US$12m
Mar 31 2023	n/a	n/a	-US$12m
Dec 31 2022	US$173k	US$32k	-US$11m
Sep 30 2022	n/a	n/a	-US$12m
Jun 30 2022	n/a	n/a	-US$12m
Mar 31 2022	n/a	n/a	-US$13m
Dec 31 2021	US$78k	n/a	-US$13m
Sep 30 2021	n/a	n/a	-US$12m
Jun 30 2021	n/a	n/a	-US$11m
Mar 31 2021	n/a	n/a	-US$10m
Dec 31 2020	US$45k	n/a	-US$9m
Sep 30 2020	n/a	n/a	-US$9m
Jun 30 2020	n/a	n/a	-US$9m
Mar 31 2020	n/a	n/a	-US$9m
Dec 31 2019	US$64k	n/a	-US$9m
Sep 30 2019	n/a	n/a	-US$8m
Jun 30 2019	n/a	n/a	-US$7m
Mar 31 2019	n/a	n/a	-US$7m
Dec 31 2018	US$53k	n/a	-US$7m
Sep 30 2018	n/a	n/a	-US$8m
Jun 30 2018	n/a	n/a	-US$9m
Mar 31 2018	n/a	n/a	-US$9m
Dec 31 2017	US$36k	n/a	-US$12m

Tazminat ve Piyasa: Bob 'nin toplam tazminatı ($USD 437.89K ), US pazarındaki benzer büyüklükteki şirketler için ortalamanın altındadır ($USD 655.02K ).

Tazminat ve Kazançlar: Bob şirketinin tazminatı, şirket kârsız olduğu sürece artırıldı.

CEO

Bob Bitterman (73 yo)

1.8yrs

Görev süresi

US$437,892

Tazminat

Mr. Robert J. Bitterman, also known as Bob, serves as Chairman at Phio Pharmaceuticals Corp. since 2012 and President and Chief Executive Officer since February 20, 2023. Mr. Bitterman served as the Interi...

Liderlik Ekibi

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Robert Bitterman	President	1.8yrs	US$437.89k	0.20% $ 5.4k
Robert Infarinato	CFO & Principal Accounting Officer	less than a year	Veri yok	Veri yok
Linda Mahoney	Senior Vice President of Development	1.5yrs	Veri yok	Veri yok
Caitlin Kontulis	Secretary	no data	Veri yok	0.074% $ 2.0k

1.5yrs

Ortalama Görev Süresi

73yo

Ortalama Yaş

Deneyimli Yönetim: PHIO 'un yönetim ekibi deneyimli olarak kabul edilmiyor ( 1.5 yıl), bu da yeni bir ekibin varlığını gösteriyor.

Yönetim Kurulu Üyeleri

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Robert Bitterman	President	12.4yrs	US$437.89k	0.20% $ 5.4k
Patricia Bradford	Independent Director	2.6yrs	US$57.86k	0.041% $ 1.1k
Curtis Lockshin	Independent Director	11.6yrs	US$50.36k	0.041% $ 1.1k
Robert Ferrara	Lead Independent Director	5.1yrs	US$70.36k	0.052% $ 1.4k
Jonathan Freeman	Independent Director	7.4yrs	US$42.86k	0.041% $ 1.1k

7.4yrs

Ortalama Görev Süresi

73yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: PHIO 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilir (ortalama görev süresi 7.4 yıldır).

Phio Pharmaceuticals Yönetim

Yönetim kriter kontrolleri 2/4

Anahtar bilgiler

Son yönetim güncellemeleri

Phio Pharmaceuticals Corp. Announces Robert M. Infarinato as New Chief Financial Officer

Phio Pharmaceuticals Corp., Annual General Meeting, Jul 20, 2023

Phio Pharmaceuticals Corp. Announces Board Appointments

Phio Pharmaceuticals Corp., Annual General Meeting, Aug 09, 2022

Phio Pharmaceuticals Corp. Announces Management Changes

Phio Pharmaceuticals Corp. Announces the Appointment of Patricia A. Bradford to Its Board of Directors

Recent updates

Price target decreased by 33% to US$36.00

Forecast to breakeven in 2025

Phio Pharmaceuticals Corp. Announces Robert M. Infarinato as New Chief Financial Officer

Phio Pharmaceuticals Corp Announces Completion of Dosing in First Patient Cohort in PH-762 Phase 1b Dose-Escalation Study

Phio Pharmaceuticals Corp. Presents New Data About Its Lead Clinical Product Candidate, PH-762

Phio Pharmaceuticals Announces Upcoming Presentations at the 81st Annual Meeting of the Society for Investigative Dermatology (SID)

Phio Pharmaceuticals Corp. Presents Data Showing INTASYL May Result in More Effective Cell Therapy for Hematological Malignancies

Phio Pharmaceuticals Corp. Announces Addition of Clinical Trial Sites At Banner Md Anderson Cancer Center, the George Washington University, and Integrity Research

Phio Pharmaceuticals Corp. Announces Patent Granted by Uspto, Strengthening the Company's Intellectual Property Position in Treating Aging Skin and Skin Disorders

Phio Pharmaceuticals Receives Non-Compliance Notice from Nasdaq

Phio Pharmaceuticals Corp. Announces First US Patient Enrolled in Phase 1B Clinical Trial with Intratumoral PH-762 anti-PD-1 Therapy for Treatment of Skin Carcinomas

Phio Pharmaceuticals Corp. Announces the Presentation of New Preclinical Data At the 38Th Annual Meeting of the Society for Immunotherapy of Cancer

Phio Pharmaceuticals Corp. Presents New Data for Targeting of BRD4 with its INTASYL Compound PH-894

Phio Pharmaceuticals Corp. Announces Dosing of First Patient in Collaborative Clinical Trial with Agonox, Inc. and Providence Cancer Institute

Phio Pharmaceuticals Corp., Annual General Meeting, Jul 20, 2023

Phio Pharmaceuticals Corp. announced that it expects to receive $3.000002 million in funding

Phio Pharmaceuticals Corp Presents Preclinical Study Showing INTASYL Treatment of NK Cells More than Doubles Ability to Kill Tumor Cells

Phio Pharmaceuticals Announces FDA Clearance to Initiate Clinical Trial of PH-762 for Treatment of Skin Carcinomas

Phio Pharmaceuticals Regains Compliance with Nasdaq Listing Requirements

Phio Pharmaceuticals Corp. Announces Positive DMC Recommendation and Continued Enrollment of Advanced Melanoma Study Without Modification

Phio Pharmaceuticals Announces New Clinical Program to Study PH-762 for the Treatment of Cutaneous Squamous Cell Carcinoma

Phio Pharmaceuticals Announces New Clinical Program to Study PH-762 for the Treatment of Cutaneous Squamous Cell Carcinoma

Phio Pharmaceuticals Corp. Announces Study Results at the 37th Annual Meeting of the Society for Immunotherapy of Cancer on November 10th and 11th

Phio Pharmaceuticals Corp. Announces Study Results at the 37th Annual Meeting of the Society for Immunotherapy of Cancer on November 10th and 11th

Phio Pharmaceuticals Corp. Announces Board Appointments

Phio Pharmaceuticals appoints interim executive chairman

Phio Pharmaceuticals Corp. Announces Preclinical Data Demonstrating PH-762 Enhances Persistence of T Cells for Tumor Cell Killing as Presented by Helmholtz Munich at the 9th Immunotherapy of Cancer Conference

Phio Pharmaceuticals Discloses Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard

Phio Pharmaceuticals GAAP EPS of -$0.19 beats by $0.12

Phio Pharmaceuticals Corp., Annual General Meeting, Aug 09, 2022

Phio Pharmaceuticals Corp. Presents New Data Demonstrating PH-894 Enhances Activity of Her2-Car T Cells At ASGCT 2022

Phio Pharmaceuticals Corp. Announces Management Changes

Phio Pharmaceuticals Corp. Announces the Appointment of Patricia A. Bradford to Its Board of Directors

Price target decreased to US$6.00

Is Phio Pharmaceuticals (NASDAQ:PHIO) In A Good Position To Deliver On Growth Plans?

Phio Pharmaceuticals Corp. Presents Positive New Data on PH-894 Demonstrating Antitumor Efficacy in Model of PD-1 Refractory Disease at AACR Annual Meeting 2022

Phio Pharmaceuticals Corp. Initiates In Vivo Studies of INTASYL Based Antivirals Against SARS-CoV-2

Phio Pharmaceuticals Announces Regulatory Clearance of Clinical Trial for PH-762 to Treat Melanoma

Price target decreased to US$6.00

Phio Pharmaceuticals Presents Data at ESMO 2021 Demonstrating Persistent Anti-Tumor Immunity with INTASYL Dual-Targeting PD-1 and BRD4

Phio Pharmaceuticals Presents New in Vivo Data At the 2021 Asco Annual Meeting Showing Dual-Targeting Intasyl Offers Increased Efficacy and Safety Potential over Other Therapeutic Approaches

Phio Pharmaceuticals Presents Positive In Vivo Data at ASGCT Showing PH-762 Significantly Enhanced Antitumor Efficacy of HER2-Targeted CAR-T Cells

Phio Pharmaceuticals and AgonOx Inc. Announces Collaboration on Clinical Development of Novel T Cell-Based Cancer Immunotherapies

Phio Pharmaceuticals Corp. has completed a Follow-on Equity Offering in the amount of $7.684001 million.

Phio Pharmaceuticals Corp. announced that it has received $14.001908 million in funding

Phio Pharmaceuticals Corp. announced that it expects to receive $14.002049 million in funding

Phio Pharmaceuticals Corp. Announces Positive in Vivo Data on Combination PD-1 and TIGIT Checkpoint Blockade with INTASYL in a Single Therapeutic for Cancer Treatment

Phio soars 22% on positive in vivo data on combination PD-1 and TIGIT therapy in cancer

CEO Tazminat Analizi

CEO

Görev süresi

Tazminat

Liderlik Ekibi

Ortalama Görev Süresi

Ortalama Yaş

Yönetim Kurulu Üyeleri

Ortalama Görev Süresi

Ortalama Yaş